Primary cytomegalovirus disease after five years of antiviral prophylaxis

被引：16

作者：

Kijpittayarit, S

Deziel, P

Eid, AJ

Razonable, RR

机构：

[1] Mayo Clin & Mayo Fdn, Div Infect Dis, Coll Med, Dept Internal Med, Rochester, MN 55905 USA

[2] Mayo Clin & Mayo Fdn, William J Von Liebig Transplant Ctr, Rochester, MN 55905 USA

来源：

TRANSPLANTATION | 2006年 / 81卷 / 01期

关键词：

D O I：

10.1097/01.tp.0000190424.30178.43

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：137 / 138

页数：2

共 5 条

[1] RECOVERY OF HLA-RESTRICTED CYTOMEGALOVIRUS (CMV)-SPECIFIC T-CELL RESPONSES AFTER ALLOGENEIC BONE-MARROW TRANSPLANT - CORRELATION WITH CMV DISEASE AND EFFECT OF GANCICLOVIR PROPHYLAXIS [J].

LI, CR ;

GREENBERG, PD ;

GILBERT, MJ ;

GOODRICH, JM ;

RIDDELL, SR .

BLOOD, 1994, 83 (07) :1971-1979

[2]

Razonable Raymund R, 2004, Herpes, V11, P77

[3] Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients [J].

Razonable, RR .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 :S7-S13

[4] Management of cytomegalovirus infection in lung transplant recipients: Evidence-based recommendations [J].

Zamora, MR ;

Davis, RD ;

Leonard, C .

TRANSPLANTATION, 2005, 80 (02) :157-163

[5] Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation [J].

Zamora, MR ;

Nicolls, MR ;

Hodges, TN ;

Marquesen, J ;

Astor, T ;

Grazia, T ;

Weill, D .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (10) :1635-1642

← 1 →